A key activation molecule which enables the body’s own immune system to fight cancer, developed by the University of Southampton, has been issued a US patent.
CD27 is found on T cells and can be manipulated by certain antibodies to fight cancer. It is this process that has been issued the patent entitled: Human immune therapies using a CD27 agonist alone or in combination with other immune modulators by the United States Patent and Trademark Office (USPTO) today (10th July 2013).
The University of Southampton has a proven record stretching back to the 1980s of taking ideas from cancer immunology research and delivering them into patient treatments, including anti-cancer antibodies and vaccines, and is probably unique in the UK for such activity. Cancer Research UK scientists, Professors Aymen Al-Shamkhani and Martin Glennie, both from the University of Southampton, are working with Celldex Therapeutics to develop a human monoclonal antibody (mAb) called CDX-1127 that activates CD27. This drug is currently in Phase 1 clinical testing for the treatment of a range of advanced solid and blood cancers.
Over the last decade, researchers around the world have realised that the body’s immune system has the capacity to reject cancer. However, this often fails because the cancer cells are seen by the immune system as part of the body and the growing cancer has the capacity to switch off the immune recognition in T cells.
Antibodies, like CDX-1127, are engineered to wake up these T cells and thereby restore the anti-cancer activity to attack the tumour. This process is already proving beneficial with other immune stimulating antibodies in phase III trials for range of cancers.
Professor Martin Glennie, Head of Cancer Sciences, says: “With the developments we are seeing from CDX-1127, and other antibodies, we will soon be able to direct the body’s natural defenses more effectively and hopefully trigger response to a level where they can control cancer for the long-term.”
The patent is assigned to the University of Southampton which issued an exclusive license to Celldex Therapeutics for the development of human anti-CD27 antibodies in November 2008. The patent includes 18 claims covering various methods of treating cancer using CD27 agonists and relates, among other things, directly to Celldex’s CD27 antibody program and therapeutic uses of Celldex’s antibody CDX-1127.
“We continue to make excellent progress advancing CDX-1127. Securing this key piece of intellectual property is an important achievement as we expand our clinical program in solid tumors and complete dose-escalation studies in hematologic malignancies,” said Tibor Keler, Senior Vice President and Chief Scientific Officer of Celldex Therapeutics. “This patent also directly speaks to the importance of the innovative work of Professor Glennie and his team at the University of Southampton in targeting members of the TNF receptor superfamily—which we believe is resulting in rapid translation of exciting immunostimulatory antibodies into the clinic.”